Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb:79:103839.
doi: 10.1016/j.breast.2024.103839. Epub 2024 Nov 14.

Treatment of oligometastatic breast cancer: The role of patient selection

Riccardo Ray Colciago  1 , Maria Carmen De Santis  2 , Carlotta Giandini  3 , Maria Grazia Carnevale  3 , Serena Di Cosimo  4
Affiliations
Review

Treatment of oligometastatic breast cancer: The role of patient selection

Riccardo Ray Colciago et al. Breast. 2025 Feb.

Abstract

Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT). This has become a valid ablative treatment option for OMD patients. However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients. We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Given her role as Editorial Board Member, Serena Di Cosimo had no involvement in the peer-review of this article and has no involvement in the peer review of this article and has no access to information regarding its peer review.

Figures

Fig. 1
Fig. 1
Comparison between SBRT responders and not.
See this image and copyright information in PMC

References

    1. Dillekås H., Rogers M.S., Straume O. Are 90% of deaths from cancer caused by metastases. Cancer Med. 2019;8(12):5574–5576. doi: 10.1002/cam4.2474. - DOI - PMC - PubMed
    1. Seyfried T.N., Huysentruyt L.C. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43–73. doi: 10.1615/critrevoncog.v18.i1-2.40. - DOI - PMC - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Arnold M., Morgan E., Rumgay H., Mafra A., Singh D., Laversanne M., et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022 Dec;66:15–23. doi: 10.1016/j.breast.2022.08.010. - DOI - PMC - PubMed
    1. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi: 10.1200/JCO.1995.13.1.8. - DOI - PubMed